Are Mangalam Drugs latest results good or bad?
Mangalam Drugs and Organics reported poor financial results for March 2025, with a Profit After Tax of only Rs 0.06 crore, a significant drop from previous quarters, and net sales declining to Rs 73.04 crore, the lowest in five quarters. The company faces increased interest expenses and reduced earnings per share, indicating serious operational challenges.
Mangalam Drugs and Organics has reported its financial results for the quarter ending March 2025, which indicate significant challenges for the company. The Profit After Tax (PAT) has fallen to Rs 0.06 crore, representing a substantial decline compared to the average PAT of Rs 2.55 crore over the previous four quarters. This sharp reduction highlights a troubling trend in the company's profitability.Net sales for the quarter were reported at Rs 73.04 crore, which is a decrease from the average net sales of Rs 86.86 crore in the prior four quarters. This figure marks the lowest sales recorded in the last five quarters, suggesting a negative trajectory in the company's financial health.
Interest expenses have reached a five-quarter high of Rs 4.03 crore, reflecting an increase in borrowing costs. Additionally, the Earnings per Share (EPS) has dropped to Rs 0.04, indicating reduced earnings for shareholders.
Overall, the financial results for Mangalam Drugs and Organics reveal significant operational challenges. The company saw an adjustment in its evaluation, reflecting the current financial difficulties.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
